Last week, in the ongoing Immunex v. Sanofi patent litigation regarding Immunex’s claims of infringement against Sanofi and Regeneron’s Dupixent® (dupilumab) product, the Defendants moved for summary judgment of invalidity of the sole patent-in-suit, the ‘487 patent, on the ground that the patent’s claims are indefinite. According to Defendants’ brief,…
As we previously reported, Immunex sued Sanofi and Regeneron earlier this year in the Central District of California alleging that the sale of Sanofi and Regeneron’s FDA-approved Dupixent® (dupilumab) product would infringe Immunex’s U.S. Patent 8,679,487. Today, the defendants in the case filed a motion to file a first amended…
Yesterday during Regeneron Pharmaceutical’s Q2 earnings call, Regeneron announced that its Antibody Discovery Agreement with Sanofi will be ending on December 31, 2017 without an extension. Regeneron’s President and Chief Scientific Officer, George D. Yancopoulos, stated that Regeneron and Sanofi will continue their collaboration with respect to drugs discovered and initially developed under…
Sanofi-Aventis has filed a petition for IPR of Immunex Corporation’s U.S. Patent 8,679,487, directed to isolated human antibodies that compete with a reference antibody for binding to human interleukin-4 (IL-4) receptor. The proceeding has been assigned the number IPR2017-01879. The ‘487 patent is also at issue in district court litigation regarding Sanofi-Aventis and Regeneron’s…
We previously reported that Sanofi and Regeneron filed a declaratory judgment action seeking a ruling that its approved Dupixent® (dupilumab) product does not infringe Amgen’s U.S. Pat. 8,679,487 (“the ’487 patent”), and that Immunex, a wholly owned subsidiary of Amgen, later filed a complaint against Sanofi and Regeneron alleging that…
On April 5, Immunex (a wholly-owned subsidiary of Amgen) filed a complaint against Sanofi and Regeneron related to Sanofi and Regeneron’s Dupixent® (dupilumab) product, which received FDA approval last week. Immunex’s complaint was filed in the District Court for the Central District of California and asserts patent infringement and seeks a declaratory judgment of…
Sanofi and Regeneron announced yesterday that their Dupixent® (dupilumab) product has received FDA approval for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. As we reported last week, Sanofi and Regeneron have filed…
This week Sanofi-Aventis and Regeneron Pharmaceuticals took aim at Amgen’s U.S. Patent No. 8,679,487 on two fronts, filing a declaratory judgment action in district court and a petition for inter partes review in the U.S. Patent & Trademark Office. The ’487 patent is directed to an “isolated human antibody that competes with…